Protagenic Therapeutics Equity Warrant Exp 13 April 2025 PTIXW:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EDT
0.018quote price arrow down-0.005 (-21.8682%)
Volume
300
52 week range
0.00 - 0.04
Loading...
  • Open0.018
  • Day High0.018
  • Day Low0.018
  • Prev Close0.023
  • 52 Week High0.04
  • 52 Week High Date04/01/24
  • 52 Week Low0.00
  • 52 Week Low Date12/20/23

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.018
  • Day High0.018
  • Day Low0.018
  • Prev Close0.023
  • 52 Week High0.04
  • 52 Week High Date04/01/24
  • 52 Week Low0.00
  • 52 Week Low Date12/20/23
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Protagenic Therapeutics Equity Warrant Exp 13 April 2025

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Protagenic Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric...
Garo Armen Ph.D.
Executive Chairman of the Board
Andrew Slee Ph.D.
Chief Operating Officer
Alexander Arrow M.D.
Chief Financial Officer
Address
149 FIFTH AVENUE, SUITE 500
New York, NY
10010
United States